UK Scientists Rushing to Create Ebola Vaccine Using COVID Jab Technology

The Gateway Pundit ^ | May 24, 2026 | Cassandra MacDonald

[Red Badger]

The effort comes as a new outbreak of the Bundibugyo strain of Ebola continues to spread in the Democratic Republic of Congo.

The Oxford Vaccine Group (OVG) announced it is urgently producing its candidate vaccine, ChAdOx1 BDBV, which could enter human clinical trials in as little as two to three months if animal testing succeeds.

The Bundibugyo Ebolavirus is one of the less common but still highly lethal strains of Ebola.

Unlike the more frequently seen Zaire strain, there are currently no licensed vaccines or specific treatments approved for Bundibugyo virus disease.

The WHO and local authorities have described the situation as “spreading rapidly,” with contact tracing and quarantine efforts underway. However, the risk to the UK and broader Europe remains low, according to the European Centre for Disease Prevention and Control (ECDC).

The candidate vaccine is a monovalent (single-strain) ChAdOx1 BDBV vaccine specifically targeting the Bundibugyo Ebolavirus.

It uses the ChAdOx1 viral vector platform, the same chimpanzee adenovirus-based technology used for the Oxford/AstraZeneca COVID-19 vaccine.

This platform was chosen because it is “highly adjustable” and can be quickly modified to target different pathogens.

In the statement, the OVG emphasized they are “working urgently” while adhering to “established scientific, ethical, and regulatory standards.”

The statement read in part:

---

TOPICS: Health/Medicine; History; Military/Veterans; Science
KEYWORDS:

[TheThirdRuffian]

You might want to read a bit more.

[jonrick46]

The polio vaccine has undergone numerous changes. Here is a sample of mRNA technology being adapted to numerous diseases. It is from the scientific paper, “mRNA Vaccines: Current Applications and Future Directions.”

https://pmc.ncbi.nlm.nih.gov/articles/PMC12572956/

“In recent years, the use of mRNA vaccines to combat various viral infections has been actively explored. Cytomegalovirus (CMV), a significant cause of congenital defects, is now targeted by Moderna’s mRNA‐1647 vaccine, which has entered phase III clinical trials and shows promise for preventing CMV infection. mRNA vaccines for Zika virus have demonstrated the ability to induce protective immunity in animal models and have progressed to clinical trials as well. Similarly, mRNA‐based rabies vaccines are currently under clinical investigation, offering the potential for more efficient and convenient pre‐ or postexposure prophylaxis. Vaccine development is also underway for herpes simplex virus using mRNA technology. Additionally, mRNA vaccines against other viruses such as Ebola and Lassa fever are in development, with researchers focusing on the genetic coding and design of key antigens. Given the lack of effective conventional vaccines for many of these viruses, mRNA technology offers the potential for rapid development of novel vaccines. mRNA platforms are highly flexible, allowing for the encoding of antigens from multiple pathogens within a single formulation, thereby enabling multivalent immunity and the creation of combination vaccines that can target multiple viruses simultaneously. The monkeypox outbreak in 2022 has further spurred research into the application of mRNA vaccines for such emerging threats. With ongoing advancements in nano delivery systems and stabilizing formulation technologies—including self‐amplifying RNA and heat‐stabilized formulations—mRNA vaccines are expected to become a crucial tool in the fight against viral diseases.

mRNA Vaccines in Cancer Therapy

Among the various vaccine candidate platforms, the early application of mRNA was limited by instability, low efficiency, and excessive immunogenicity. However, the successful development of the SARS‐CoV‐2 mRNA vaccine overcame these technological bottlenecks in vaccine preparation. This breakthrough has enabled the rapid, economical production of tumor mRNA vaccines with improved stability and efficiency. In this context, we will discuss the application of mRNA vaccines in tumor immunotherapy, as well as current advances in targeted and personalized mRNA vaccines.

mRNA Vaccines in Tumor Immunotherapy

The application of mRNA vaccines in tumor immunotherapy primarily relies on encoding TAAs or TSAs to activate the immune system for targeted attacks on tumor cells. These vaccines efficiently stimulate APCs in vivo, promoting a synergistic effect between innate and adaptive immune responses. In clinical practice, mRNA vaccines are classified as either prophylactic or therapeutic: prophylactic vaccines aim to prevent tumor development in high‐risk populations by encoding tumor antigens, while therapeutic vaccines target patients with existing tumors, eliciting immune responses to attack and eliminate cancer cells. In recent years, mRNA tumor vaccines have demonstrated significant promise in clinical trials for various cancer types. Sahin found that mRNA vaccines induced a strong immune response in patients with melanoma, which was notably enhanced when combined with ICIs. Similarly, Yuan showed that personalized vaccines targeting RNA mutations triggered multspecific and therapeutic immune responses against cancer. Furthermore, a review by Miao confirmed the promising application of mRNA vaccines in treating a range of aggressive solid tumors, such as non‐small cell lung cancer (NSCLC), colorectal cancer, and melanoma. mRNA vaccines are efficiently delivered to target cells using LNP‐based vectors. Once inside the cell, mRNA is internalized into endosomes. Protonation of ionizable lipids in the acidic endosomal environment promotes membrane fusion, leading to the release of mRNA into the cytoplasm, where it is translated into protein. These proteins are degraded by the proteasome into antigenic peptides, which are then presented on MHC molecules to CD8⁺ T cells, thereby activating cell‐mediated immune responses demonstrated that nanomaterial‐based delivery systems significantly enhance the immunogenicity of mRNA vaccines and exert antitumor effects via the Toll‐like receptor 4 signaling pathway. mRNA vaccines activate APCs such as dendritic cells (DCs) and macrophages, enabling them to process exogenous antigens and present them through MHC molecules. Cells display exogenous antigens to CD4⁺ T cells via MHC‐II and facilitate cross‐presentation to CD8⁺ T cells via MHC‐I. Mature DCs secrete proinflammatory and immunostimulatory cytokines—including IL‐12, IL‐23, and IL‐1β and subsequently migrate to tumor‐draining lymph nodes. Zhou reported that incorporating a STING agonist in mRNA vaccine design can substantially increase the effectiveness of cancer immunotherapy, promoting immune cell activation and antitumor responses through intelligently designed nanovaccines. Peptides presented on DC surface MHC molecules interact with T cell receptors (TCRs), activating naïve CD8⁺ T cells and differentiating them into CTLs under the combined influence of multiple receptors and cytokines. These CTLs can infiltrate tissues and target tumor cells, exerting potent antitumor effects [80]. A study by Melamed et showed that mRNA delivered via ionizable LNPs can be efficiently targeted to pancreatic β‐cells to induce robust CTL responses. Importantly, mRNA vaccines are also capable of inducing memory T cell formation, enabling rapid and long‐lasting protection upon re‐exposure to the same antigen. He highlighted the potential of mRNA cancer vaccines in inducing durable immune memory.”